<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of inflammatory demyelinating diseases of the central nervous system</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of inflammatory demyelinating diseases of the central nervous system</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of inflammatory demyelinating diseases of the central nervous system</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Attribute</td> <td class="subtitle1">MOGAD</td> <td class="subtitle1">AQP4-NMOSD</td> <td class="subtitle1">Multiple sclerosis</td> </tr> <tr class="divider_bottom"> <td><strong>Antecedent infection/immunization</strong></td> <td>Common</td> <td>Rare</td> <td>Rare</td> </tr> <tr class="divider_bottom"> <td><strong>Ages affected</strong></td> <td>Any (children and young adults more predisposed; median age of onset in third decade)</td> <td>Any (median age at onset in fourth decade)</td> <td>Any (median age at onset in third decade)</td> </tr> <tr class="divider_bottom"> <td><strong>Sex (female:male)</strong></td> <td>1:1</td> <td>9:1</td> <td>2:1</td> </tr> <tr class="divider_bottom"> <td><strong>Epidemiology</strong></td> <td> <p>Prevalence: rare</p> <p>Race/ethnicity: no predilection yet identified</p> Geographic: variable</td> <td> <p>Prevalence: rare</p> <p>Race/ethnicity: African American and Afro-Caribbean individuals more predisposed</p> Geographic: higher proportion of total demyelinating disease is AQP4-IgG positive NMOSD in regions where multiple sclerosis prevalence is low</td> <td> <p>Prevalence: common</p> <p>Race/ethnicity: White individuals are more predisposed</p> Geographic: higher prevalence in regions farthest from equator</td> </tr> <tr class="divider_bottom"> <td><strong>Most common manifestations</strong></td> <td> <p>Initial episode: optic neuritis (with optic disc edema in &gt;85%), ADEM, NMOSD, myelitis, unilateral cortical encephalitis</p> Relapse: optic neuritis</td> <td>NMOSD (any combination of myelitis, optic neuritis, area postrema syndrome)</td> <td>Myelitis, optic neuritis, brainstem, cerebral episodes; myelopathy for progressive multiple sclerosis</td> </tr> <tr class="divider_bottom"> <td><strong>Course</strong></td> <td>Monophasic or relapsing; no reports of secondary progression</td> <td>Typically relapsing; usually no secondary progression</td> <td>Relapsing-remitting from onset in 85% (most later develop secondary progression); 10 to 15% progressive from onset</td> </tr> <tr class="divider_bottom"> <td><strong>Attack severity</strong></td> <td>Usually moderate to severe</td> <td>Usually moderate to severe</td> <td>Usually mild to moderate</td> </tr> <tr class="divider_bottom"> <td><strong>Recovery from attacks</strong></td> <td>Good</td> <td>Often incomplete</td> <td>Good</td> </tr> <tr class="divider_bottom"> <td><strong>CSF</strong></td> <td>White blood cell count variable (lymphocytic); oligoclonal bands in 5 to 20%</td> <td>White blood cell count variable (usually lymphocytic but can be neutrophilic or eosinophilic); oligoclonal bands in 30%</td> <td>White blood cell count &lt;50/mm<sup>3</sup> × 10<sup>6</sup>/L (lymphocytic) or can be normal; oligoclonal bands in 85%</td> </tr> <tr class="divider_bottom"> <td><strong>Blood biomarker</strong></td> <td>MOG-IgG (false positives may occur)</td> <td>AQP4-IgG (false positives very rare)</td> <td>NA</td> </tr> <tr class="divider_bottom"> <td><strong>Brain MRI</strong></td> <td>ADEM-like fluffy white matter, deep gray matter, diffuse/confluent brainstem including cerebellar peduncles, unilateral cortical swelling, leptomeningeal enhancement</td> <td>Often normal/nonspecific; if present, area postrema, peri- third/fourth ventricle, splenium, diffuse corpus callosum, pencil-thin ependymal or cloud enhancement</td> <td>Ovoid periventricular (Dawson fingers), juxtacortical, cortical, infratentorial peripheral, ring-/open ring-enhancing</td> </tr> <tr class="divider_bottom"> <td><strong>Optic nerve MRI</strong></td> <td>Unilateral or bilateral; enhancement of &gt;50% of optic nerve; anterior optic pathway (hence optic disc edema common)</td> <td>Unilateral or bilateral; enhancement of &gt;50% of optic nerve; posterior optic pathway involving chiasm</td> <td>Usually unilateral; enhancement of &lt;50% of nerve affected; middle of optic nerve</td> </tr> <tr class="divider_bottom"> <td><strong>Spine MRI</strong></td> <td>Multiple lesions (75% longitudinally extensive transverse myelitis; 25% short); conus involved; central on axial, often with H-sign; enhancement &lt;50%</td> <td>Single lesion (longitudinally extensive transverse myelitis 85%; short 15%); central on axial; ring or variable enhancement</td> <td>Multiple lesions; short lesions; periphery of cord (dorsal/lateral column); ring or variable enhancement</td> </tr> <tr class="divider_bottom"> <td><strong>Acute treatment</strong></td> <td>IV glucocorticoids; plasma exchange (sometimes required); IVIG (used in children)</td> <td>IV glucocorticoids; plasma exchange (often required)</td> <td>IV glucocorticoids; plasma exchange (rarely required)</td> </tr> <tr class="divider_bottom"> <td><strong>Maintenance treatment</strong></td> <td>None approved; none needed if monophasic; glucocorticoids-sparing for relapsing disease (azathioprine, IVIG mycophenolate, methotrexate, rituximab)</td> <td> <p>FDA-approved medications in the United States: eculizumab, inebilizumab, and satralizumab</p> Off label: azathioprine, mycophenolate, rituximab, tocilizumab</td> <td>Variety of approved immunomodulatory medications</td> </tr> <tr> <td><strong>Prognosis</strong></td> <td>Most disability with first attack; transient seropositivity predicts monophasic course; persistent seropositivity and high titer predict relapsing disease</td> <td>Attack-related accumulation of disability; secondary progression rarely if ever occurs</td> <td>Majority ambulatory after 20 years; most disability occurs in progressive phase</td> </tr> </tbody></table></div><div class="graphic_footnotes">MOGAD: myelin oligodendrocyte glycoprotein antibody associated disease; AQP4-NMOSD: aquaporin-4 neuromyelitis optica spectrum disorder; IgG: immunoglobulin G; ADEM: acute disseminated encephalomyelitis; CSF: cerebrospinal fluid; MOG: myelin oligodendrocyte glycoprotein; NA: not applicable; IV: intravenous; IVIG: intravenous immune globulin; MRI: magnetic resonance imaging; FDA: US Food and Drug Administration.</div><div class="graphic_reference">From: Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Continuum (Minneap Minn) 2019; 25:815. DOI: <a href="https://journals.lww.com/continuum/Fulltext/2019/06000/Neuromyelitis_Optica_Spectrum_Disorder_and_Other.15.aspx" target="_blank">10.1212/CON.0000000000000742</a>. Copyright © 2019 American Academy of Neurology. Adapted with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 131849 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
